Another great post by JFM to a basher: XXXXXXXX
Post# of 72440
(Total Views: 581)
Posted On: 02/03/2021 9:58:49 AM
Another great post by JFM to a basher:
XXXXXXXXXX...
Your attempt to discredit another post, which noted:
Brilacidin via RBL's “... has proven to be over 90 percent effective in destroying Covid-19 AND its variants in lab results”
by asserting:
"Incorporating such obvious “inaccuracies “ into your communications will diminish their impact considerably"
...is like spitting in the wind!
I AGREE...that INCORPORATING SUCH OBVIOUS INACCURACIES...DIMINISH COMMUNICATIONS IMPACT...AS WITH YOURS!!!
But...by also posting:
"Once again your statement that brilacidin has been shown to be effective against variant COVID-19 strains is flat out false."
...is in itself...FLAT OUT FALSE.
Tyrus603...was obviously using "effective" as meaning the REDUCTION IN COVID-19 VIRAL LOAD, using human tissue, as much as 97% as reported by RBL after extensive testing ... ...
WHICH IS ABSOLUTELY CORRECT...
...unless of course you are implying that we are to believe that what Rutgers Univ. and GMU Univ. reported...i.e. the REDUCTIONS IN VIRAL LOADS up to 97% in their labs...was some kind of co-conspiracy by the Labs...with Leo/CEO in publishing the PR below...
...and that they together fooled the FDA accepting those (your) "alleged inaccuracies" resulting in the...
FDA GRANTING ..."INVESTIGATIONAL NEW DRUG" approval AND "FAST TRACT DESIGNATION"...just last month!
YES...“inaccuracies “ into your communications will diminish their impact considerably"!!!
Read PRESS RELEASE SUMMARIZING ... INDEPENDENT GOV SPONSORED lab results for Brilacidin:
http://www.ipharminc.com/press-release/2020/6...-cell-line
· "Brilacidin is a unique 3-in-1 antiviral, anti-inflammatory, antimicrobial COVID-19 drug candidate..."
"Brilacidin exhibited a statistically significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human lung epithelial cell line—reducing viral load by 95 percent and by 97 percent, compared to control, at two therapeutic concentrations tested. Based on a CC50 value—the concentration of drug at which 50 percent of cells maintain viability—Brilacidin was also shown to be non-cytotoxic in the lung cell line.
The new lung cell line data reinforce previous testing conducted at the RBL, in VERO cells, where Brilacidin showed a similar robust inhibition, of 75 percent, against SARS-CoV-2 compared to control. Brilacidin has also been shown, in testing at the RBL, to be non-cytotoxic in VERO cells."
“Brilacidin has now demonstrated potent inhibition of SARS-CoV-2 in human lung and kidney cell lines, and in VERO cells, in laboratory testing conducted by independent academic researchers at two institutions, both of whom plan to submit their findings for peer-review publication,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “The antiviral data we are compiling provides compelling proof of Brilacidin’s impressive ability to inhibit the novel coronavirus, toward initiating a clinical study of Brilacidin for COVID-19.”
PS. Those clinical trials...are EXPECTED TO BE INITIATED THIS WEEK...to prove out the lab results in humans!
XXXXXXXXXX...
Your attempt to discredit another post, which noted:
Brilacidin via RBL's “... has proven to be over 90 percent effective in destroying Covid-19 AND its variants in lab results”
by asserting:
"Incorporating such obvious “inaccuracies “ into your communications will diminish their impact considerably"
...is like spitting in the wind!
I AGREE...that INCORPORATING SUCH OBVIOUS INACCURACIES...DIMINISH COMMUNICATIONS IMPACT...AS WITH YOURS!!!
But...by also posting:
"Once again your statement that brilacidin has been shown to be effective against variant COVID-19 strains is flat out false."
...is in itself...FLAT OUT FALSE.
Tyrus603...was obviously using "effective" as meaning the REDUCTION IN COVID-19 VIRAL LOAD, using human tissue, as much as 97% as reported by RBL after extensive testing ... ...
WHICH IS ABSOLUTELY CORRECT...
...unless of course you are implying that we are to believe that what Rutgers Univ. and GMU Univ. reported...i.e. the REDUCTIONS IN VIRAL LOADS up to 97% in their labs...was some kind of co-conspiracy by the Labs...with Leo/CEO in publishing the PR below...
...and that they together fooled the FDA accepting those (your) "alleged inaccuracies" resulting in the...
FDA GRANTING ..."INVESTIGATIONAL NEW DRUG" approval AND "FAST TRACT DESIGNATION"...just last month!
YES...“inaccuracies “ into your communications will diminish their impact considerably"!!!
Read PRESS RELEASE SUMMARIZING ... INDEPENDENT GOV SPONSORED lab results for Brilacidin:
http://www.ipharminc.com/press-release/2020/6...-cell-line
· "Brilacidin is a unique 3-in-1 antiviral, anti-inflammatory, antimicrobial COVID-19 drug candidate..."
"Brilacidin exhibited a statistically significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human lung epithelial cell line—reducing viral load by 95 percent and by 97 percent, compared to control, at two therapeutic concentrations tested. Based on a CC50 value—the concentration of drug at which 50 percent of cells maintain viability—Brilacidin was also shown to be non-cytotoxic in the lung cell line.
The new lung cell line data reinforce previous testing conducted at the RBL, in VERO cells, where Brilacidin showed a similar robust inhibition, of 75 percent, against SARS-CoV-2 compared to control. Brilacidin has also been shown, in testing at the RBL, to be non-cytotoxic in VERO cells."
“Brilacidin has now demonstrated potent inhibition of SARS-CoV-2 in human lung and kidney cell lines, and in VERO cells, in laboratory testing conducted by independent academic researchers at two institutions, both of whom plan to submit their findings for peer-review publication,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “The antiviral data we are compiling provides compelling proof of Brilacidin’s impressive ability to inhibit the novel coronavirus, toward initiating a clinical study of Brilacidin for COVID-19.”
PS. Those clinical trials...are EXPECTED TO BE INITIATED THIS WEEK...to prove out the lab results in humans!
(4)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼